GAMMA Investing LLC Has $6.36 Million Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

GAMMA Investing LLC grew its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 17,558.4% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 95,002 shares of the specialty pharmaceutical company's stock after buying an additional 94,464 shares during the period. GAMMA Investing LLC owned 0.44% of ANI Pharmaceuticals worth $6,360,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of ANI Pharmaceuticals by 3.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,523 shares of the specialty pharmaceutical company's stock worth $582,000 after purchasing an additional 364 shares during the last quarter. Natixis Advisors LLC increased its position in shares of ANI Pharmaceuticals by 2.3% during the fourth quarter. Natixis Advisors LLC now owns 18,601 shares of the specialty pharmaceutical company's stock worth $1,028,000 after acquiring an additional 417 shares during the last quarter. US Bancorp DE increased its holdings in ANI Pharmaceuticals by 842.9% in the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock valued at $33,000 after buying an additional 531 shares during the last quarter. KBC Group NV boosted its stake in ANI Pharmaceuticals by 89.2% in the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock valued at $70,000 after acquiring an additional 600 shares during the period. Finally, MetLife Investment Management LLC boosted its stake in ANI Pharmaceuticals by 6.3% in the fourth quarter. MetLife Investment Management LLC now owns 11,397 shares of the specialty pharmaceutical company's stock valued at $630,000 after acquiring an additional 675 shares during the period. Hedge funds and other institutional investors own 76.05% of the company's stock.

ANI Pharmaceuticals Stock Performance

ANIP traded up $0.44 during midday trading on Friday, reaching $62.56. The company's stock had a trading volume of 150,686 shares, compared to its average volume of 309,744. The stock has a market cap of $1.36 billion, a P/E ratio of -113.75 and a beta of 0.55. The company has a fifty day simple moving average of $64.74 and a 200 day simple moving average of $61.08. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals, Inc. has a twelve month low of $52.50 and a twelve month high of $77.00.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.37 by $0.33. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm had revenue of $197.12 million for the quarter, compared to analyst estimates of $179.75 million. During the same quarter last year, the firm posted $0.82 EPS. The company's revenue was up 43.4% on a year-over-year basis. Research analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

Insider Buying and Selling

In other ANI Pharmaceuticals news, insider Christopher Mutz sold 4,000 shares of the company's stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $60.45, for a total transaction of $241,800.00. Following the completion of the sale, the insider now owns 107,317 shares in the company, valued at approximately $6,487,312.65. The trade was a 3.59% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Meredith Cook sold 400 shares of the company's stock in a transaction on Monday, April 14th. The shares were sold at an average price of $68.96, for a total transaction of $27,584.00. Following the completion of the sale, the vice president now owns 80,145 shares of the company's stock, valued at approximately $5,526,799.20. This represents a 0.50% decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,281 shares of company stock worth $322,306 in the last quarter. Insiders own 12.70% of the company's stock.

Wall Street Analysts Forecast Growth

ANIP has been the subject of several analyst reports. JPMorgan Chase & Co. initiated coverage on ANI Pharmaceuticals in a research report on Wednesday, March 12th. They set an "overweight" rating and a $85.00 price objective for the company. Guggenheim reiterated a "buy" rating and set a $86.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, May 12th. HC Wainwright reiterated a "buy" rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. Truist Financial boosted their price objective on ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a "hold" rating in a research report on Monday, April 21st. Finally, Wall Street Zen downgraded ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday, April 24th. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, ANI Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $80.13.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.